First Time Loading...

Poseida Therapeutics Inc
NASDAQ:PSTX

Watchlist Manager
Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc
NASDAQ:PSTX
Watchlist
Price: 2.02 USD 1% Market Closed
Updated: Apr 20, 2024

Intrinsic Value

PSTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies an... [ Read More ]

The intrinsic value of one PSTX stock under the Base Case scenario is 2.37 USD. Compared to the current market price of 2.02 USD, Poseida Therapeutics Inc is Undervalued by 15%.

Key Points:
PSTX Intrinsic Value
Base Case
2.37 USD
Undervaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Poseida Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PSTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Poseida Therapeutics Inc

Provide an overview of the primary business activities
of Poseida Therapeutics Inc.

What unique competitive advantages
does Poseida Therapeutics Inc hold over its rivals?

What risks and challenges
does Poseida Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Poseida Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Poseida Therapeutics Inc.

Provide P/S
for Poseida Therapeutics Inc.

Provide P/E
for Poseida Therapeutics Inc.

Provide P/OCF
for Poseida Therapeutics Inc.

Provide P/FCFE
for Poseida Therapeutics Inc.

Provide P/B
for Poseida Therapeutics Inc.

Provide EV/S
for Poseida Therapeutics Inc.

Provide EV/GP
for Poseida Therapeutics Inc.

Provide EV/EBITDA
for Poseida Therapeutics Inc.

Provide EV/EBIT
for Poseida Therapeutics Inc.

Provide EV/OCF
for Poseida Therapeutics Inc.

Provide EV/FCFF
for Poseida Therapeutics Inc.

Provide EV/IC
for Poseida Therapeutics Inc.

Show me price targets
for Poseida Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Poseida Therapeutics Inc?

How accurate were the past Revenue estimates
for Poseida Therapeutics Inc?

What are the Net Income projections
for Poseida Therapeutics Inc?

How accurate were the past Net Income estimates
for Poseida Therapeutics Inc?

What are the EPS projections
for Poseida Therapeutics Inc?

How accurate were the past EPS estimates
for Poseida Therapeutics Inc?

What are the EBIT projections
for Poseida Therapeutics Inc?

How accurate were the past EBIT estimates
for Poseida Therapeutics Inc?

Compare the revenue forecasts
for Poseida Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Poseida Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Poseida Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Poseida Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Poseida Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Poseida Therapeutics Inc with its peers.

Analyze the financial leverage
of Poseida Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Poseida Therapeutics Inc.

Provide ROE
for Poseida Therapeutics Inc.

Provide ROA
for Poseida Therapeutics Inc.

Provide ROIC
for Poseida Therapeutics Inc.

Provide ROCE
for Poseida Therapeutics Inc.

Provide Gross Margin
for Poseida Therapeutics Inc.

Provide Operating Margin
for Poseida Therapeutics Inc.

Provide Net Margin
for Poseida Therapeutics Inc.

Provide FCF Margin
for Poseida Therapeutics Inc.

Show all solvency ratios
for Poseida Therapeutics Inc.

Provide D/E Ratio
for Poseida Therapeutics Inc.

Provide D/A Ratio
for Poseida Therapeutics Inc.

Provide Interest Coverage Ratio
for Poseida Therapeutics Inc.

Provide Altman Z-Score Ratio
for Poseida Therapeutics Inc.

Provide Quick Ratio
for Poseida Therapeutics Inc.

Provide Current Ratio
for Poseida Therapeutics Inc.

Provide Cash Ratio
for Poseida Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Poseida Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Poseida Therapeutics Inc?

What is the current Free Cash Flow
of Poseida Therapeutics Inc?

Financials

Balance Sheet Decomposition
Poseida Therapeutics Inc

Current Assets 226.5m
Cash & Short-Term Investments 212.2m
Receivables 9m
Other Current Assets 5.3m
Non-Current Assets 47.4m
PP&E 40.8m
Intangibles 5.5m
Other Non-Current Assets 1.1m
Current Liabilities 71.3m
Accounts Payable 3.3m
Accrued Liabilities 33.6m
Other Current Liabilities 34.4m
Non-Current Liabilities 98.9m
Long-Term Debt 58.6m
Other Non-Current Liabilities 40.3m
Efficiency

Earnings Waterfall
Poseida Therapeutics Inc

Revenue
64.7m USD
Operating Expenses
-194.2m USD
Operating Income
-129.5m USD
Other Expenses
6.1m USD
Net Income
-123.4m USD

Free Cash Flow Analysis
Poseida Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

PSTX Profitability Score
Profitability Due Diligence

Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Poseida Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

PSTX Solvency Score
Solvency Due Diligence

Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
44/100
Solvency
Score

Poseida Therapeutics Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PSTX Price Targets Summary
Poseida Therapeutics Inc

Wall Street analysts forecast PSTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PSTX is 14.28 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

Lowest
Price Target
10.1 USD
400% Upside
Average
Price Target
14.28 USD
607% Upside
Highest
Price Target
21 USD
940% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PSTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PSTX Price
Poseida Therapeutics Inc

1M 1M
-32%
6M 6M
-14%
1Y 1Y
-24%
3Y 3Y
-76%
5Y 5Y
-87%
10Y 10Y
-87%
Annual Price Range
2.02
52w Low
1.62
52w High
4.13
Price Metrics
Average Annual Return -27.38%
Standard Deviation of Annual Returns 9.04%
Max Drawdown -90%
Shares Statistics
Market Capitalization 193.2m USD
Shares Outstanding 96 490 000
Percentage of Shares Shorted 5.76%

PSTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

193.2m USD

Dividend Yield

0%

Description

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

Contact

CALIFORNIA
San Diego
9390 Towne Centre Drive, Suite 200
+18587793100.0
https://poseida.com/

IPO

2020-07-10

Employees

263

Officers

Executive Chairman of the Board
Mr. Mark J. Gergen J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Mr. Harry J. Leonhardt Esq., J.D.
President of Gene Therapy
Mr. Brent Warner
President, CEO & Director
Dr. Kristin Yarema Ph.D.
Chief Financial Officer
Ms. Johanna M. Mylet CPA
Chief Operations Officer
Mr. Loren Wagner
Show More
Chief People & Administration Officer
Ms. Kristin Martin
Senior VP of Investor Relations & Corporate Communications
Mr. Alexander Chapman
Chief Scientific Officer of Cell Therapy
Dr. Devon J. Shedlock Ph.D.
Senior Vice President of Regulatory Affairs
Ms. Lisa Portale
Show Less

See Also

Discover More
What is the Intrinsic Value of one PSTX stock?

The intrinsic value of one PSTX stock under the Base Case scenario is 2.37 USD.

Is PSTX stock undervalued or overvalued?

Compared to the current market price of 2.02 USD, Poseida Therapeutics Inc is Undervalued by 15%.